Premium
Leishmaniasis recidiva cutis due to Leishmania ( Viannia ) panamensis in subtropical Ecuador: isoenzymatic characterization
Author(s) -
Calvopina Manuel,
Uezato Hiroshi,
Gomez Eduardo A.,
Korenaga Masataka,
aka Shigeo,
Hashiguchi Yoshihisa
Publication year - 2006
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4632.2004.02518.x
Subject(s) - leishmaniasis , cutaneous leishmaniasis , leishmania , medicine , cutis , histopathology , pathology , dermatology , leishmania mexicana , lesion , parasite hosting , world wide web , computer science
Background Information regarding leishmaniasis recidiva cutis (LRC), a clinical variant of cutaneous leishmaniasis, in the New World is scarce. LRC is characterized by slowly progressing lesion(s) that appear after a variable period of time, from months to years, in or around the scar of an apparently clinically healed sore. Patients and methods Six patients are reported who presented with crusted, papular lesions located on the edge of a healed scar, with a mean of 18.2 months of slowly progressive evolution. The isolated strains of Leishmania parasites were characterized by enzyme electrophoresis. Eleven enzyme systems were assayed. Skin biopsies from the active border of the lesions were taken for histopathology. Results Tissue sections showed a granulomatous, lymphohistiocytic, dermal infiltrate containing Langhans’ giant cells. The anamnestic data, together with the clinical and histopathologic findings, support the diagnosis of LRC. The isoenzyme profile of Leishmania parasites isolated from five of the six patients identified them as Leishmania ( Viannia ) panamensis . Conclusions These findings are the first reported evidence of LRC within the clinical spectrum of American tegumentary leishmaniasis in Ecuador, and of its causative agent. The existence of LRC has future implications for both disease treatment and vaccine development.